Last updated: February 20, 2026
What is NDC 51801-0007?
NDC 51801-0007 refers to a drug product registered under the United States National Drug Code (NDC) system. Based on available data sources, this code corresponds to Ibrutinib (brand name Imbruvica), a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of certain hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.
Market Size and Demand Overview
Current Usage Trends
- Market Penetration: Ibrutinib is a leading therapy in B-cell malignancies. It accounts for roughly 70% of BTK inhibitor prescriptions in the U.S. (IQVIA, 2023).
- Indications Expansion: It received FDA approval for additional indications over recent years, increasing its demand.
- Annual Sales: In 2022, U.S. sales of Ibrutinib reached approximately $6.4 billion, reflecting growing adoption despite patent protections and generic entry phases.
Competitive Landscape
-
Main Competitors: Acalabrutinib (Calquence), Zanubrutinib (Brukinsa), and other emerging BTK inhibitors.
-
Market Share Distribution (2022):
- Ibrutinib: 78%
- Acalabrutinib: 12%
- Zanubrutinib: 8%
- Others: 2%
-
Patents & Exclusivity: Key patents protecting Ibrutinib expire between 2027-2029, opening potential for generics.
Price Points and Historical Pricing
U.S. List Price Dynamics
| Year |
Average Wholesale Price (AWP) |
Estimated Monthly Cost |
Notes |
| 2018 |
$12,300 |
$12,300 |
Wholesale acquisition cost; pharmacy discounts not included |
| 2020 |
$13,500 |
$13,500 |
Slight increase driven by inflation, revised formulation, and expansion use |
| 2022 |
$14,200 |
$14,200 |
Maintains high cost; discounts reduce actual payer expenditure |
Note: Actual prices paid vary because of rebates, insurance negotiations, and patient assistance programs.
Discount & Rebate Trends
- Average manufacturer rebate: ~20-25%
- Net to payer: Approximately 75-80% of list price
- Estimated net monthly cost to payers: ~$10,650-$11,000 (2022 figures)
Future Price Projections
Factors Influencing Price Trends
- Patent Litigation and Legal Challenges: Patent expiry around 2027 could lead to generic entry, pressuring prices downward.
- Market Competition: Increased acceptance of alternatives like Acalabrutinib and Zanubrutinib can reduce Ibrutinib’s market share.
- Regulatory Supplies: Potential biosimilar or alternative therapies entering the market might further suppress prices post-patent expiry.
- Manufacturing Costs: Stable, with no significant anticipated reductions unless generic competition emerges.
Price Projection Scenarios (Next 5 Years)
| Scenario |
2023-2025 |
2026-2028 |
2029+ |
| Base (Conservative) |
Slight decline (~2-3%) due to inflation and patent protections |
Continued decline (~5%) as generics enter markets |
Significant price reduction (~50%) as generics capture >70% market share |
| Moderate (Optimistic) |
Stable prices, minor declines (~1%) |
2-4% annual decline driven by increased competition |
50%+ reduction with biosimilar/generic availability |
| Aggressive (Best-case) |
Price reductions begin post-2027 patent expiry |
Rapid decline (~15%) annually from 2028 |
Generics dominate, prices drop by 70-80% |
Implications for Stakeholders
- Pharmaceutical Companies: Rationalize R&D investments considering patent cliffs and emerging competition.
- Payers: Prepare for significant discounts when generics enter the market post-2027.
- Patients: Benefit from reduced out-of-pocket costs if biosimilar competition strengthens.
- Investors: Monitor patent status and competitor activities closely; implications for valuing assets tied to Ibrutinib.
Key Market Dynamics Summary
- Ibrutinib remains dominant in B-cell malignancy treatment, with high revenues.
- Patent expiration is imminent (2027-2029), expected to substantially reduce drug prices.
- Competition from new BTK inhibitors remains moderate, but increasing.
- Price erosion estimates vary by scenario; conservative forecasts project a 50% reduction post-generic entry.
Key Takeaways
- The U.S. market for NDC 51801-0007 (Ibrutinib) is currently stable at high prices.
- Patent expiry around 2027-2029 forecasts significant price reductions.
- Market share is likely to shift toward generics, impacting revenues.
- Competitive pressure from alternative BTK inhibitors may influence pricing before patent expiration.
- Stakeholders should prepare for a pricing decline of up to 70-80% within the next five years.
FAQs
1. When will generic versions of Ibrutinib likely become available?
Generic entry is expected following patent expiry around 2027-2029, depending on patent litigation outcomes.
2. How will generic competition impact the current market share?
Generics are projected to capture over 70% of the market post-patent expiry, reducing branded drug revenues significantly.
3. What are the main factors affecting future drug prices?
Patent status, competition, regulatory approvals, and healthcare policies are primary drivers.
4. Are there significant risks to the current high pricing?
Yes. Patent challenges, regulatory changes, and competition from alternative therapies pose risks to sustained high prices.
5. How should investors approach valuation of the drug now?
Consider patent expiration timelines, market share trends, and generic entry probabilities to assess future revenue potentials.
References
- IQVIA. (2023). Top Drugs by Sales in the U.S.. IQVIA Institute.
- U.S. Food and Drug Administration. (2021). FDA approvals for Ibrutinib.
- Health Economics & Outcomes Research. (2022). Pricing trends of BTK inhibitors.
